Global
Multiple Myeloma Market: Overview
Cancer
begins when the cells in the human body start growing out of control. Nearly in
any body part, cells can become cancerous and spread to different parts of the
body. Multiple Myeloma is a type of cancer which is formed by malignant plasma
cells. The normal plasma cells are basically found in bone marrow and are thus
an important part of the immune system. Our immune system is made of various
cells working together to combat infections and other different types of
diseases. Lymphocytes are the chief cell type in the human immune system. The
key lymphocytes are B cells and T cells. B cells mature and convert into plasma
cells when they respond to an infection. Plasma cells help in creating the
antibodies that enhance the immunity system of the body and kills germs.
However, when these plasma cells grow out of control and become cancerous, they
are likely to generate a tumor known as plasmacytoma. These tumors are
basically formed in the bone, but at times can also be formed in other tissues.
If a patient is suffering from just a single plasma cell tumor, it is known as
isolated plasmacytoma and if it is more than one plasmacytoma, then it is
called multiple myeloma.
The plasma
cells in a person’s body suffering from multiple myeloma, tend to crowd out
normal blood, thus forming cells resulting in low blood counts. This also leads
to anemia which is the lack of red blood cells. Multiple myeloma also leads to
the lowering of platelets level in the blood. This further leads to a rise on
bruising and bleeding. Another severe condition that a patient develops is
leukopenia which is the dearth of the normal white blood cells, thus causing
immunity problems. Myeloma further hinders the working of the bones and their
strength. It makes them fragile by signaling the new bone or osteoblasts to
speed up the bone dissolving process. As a result of this, before a new bone is
formed, the old bone breaks. The rising bone breakage also leads to calcium
deficiency in the human body. Moreover, abnormal plasma cells fail to protect
the human body from severe infections. In the case of multiple myeloma, the
normal plasma cells crowd out, failing to produce the antibodies that fight
bacteria. The antibodies made by the myeloma cells do not help in fighting
infections. It is because the myeloma cells are basically multiple copies of
the same plasma cell – all making the exact copies of the same (or monoclonal)
antibody. Likewise, the antibodies produced by myeloma cells can also harm the
kidneys. This can cause kidney damage and also kidney failure.
The report
is a complete analysis of the growth trajectory in terms of the past, present,
and future progress and prospects of the global multiple myeloma market. It
offers an assessment of the aspects that are expected to impact the growth of
the market and the principal trends have also been mentioned in the study. The
report also offers a diverse outlook of the competitive scenario of the market
by utilizing the value chain and Porter’s five forces analysis. The report
highlights the research and development projects, mergers and acquisitions,
details on collaborations and licensing. The study provides insights into the
marketing strategies, products, and shares of the key players operating in the
market.
Global
Multiple Myeloma Market: Trends and Opportunities
The global
multiple myeloma market is likely to be driven by the shift in the lifestyle of
consumers and growing cases of plasma cancer across the globe. The rising
penetration of cancer drugs such as Revlimid and their amalgamation with the
upcoming therapies is expected to bode well for the growth of the global
multiple myeloma market. The development of new drugs and investment in
research and development projects by government and non-government
organizations is further expected to boost the market growth.
Global
Multiple Myeloma Market: Regional Outlook
The growing
economic development in Asia Pacific and Latin America is expected to provide
vendors in the global multiple myeloma market with lucrative growth prospects.
With numerous drugs in pipelines, the market North America and Europe are also
expected to grow significantly.
Companies
Mentioned in the Report
Some of the
leading companies in the multiple myeloma market are Onyx Pharmaceuticals,
Bristol-Myers Squibb, Novartis, Pfizer, Johnson and Johnson, and Celgene
Corporation.
More Trending
Reports by Transparency Market Research:
About Us
Transparency Market
Research is a global market intelligence company, providing global business
information reports and services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insights for thousands
of decision-makers. Our experienced team of analysts, researchers, and
consultants use proprietary data sources and various tools and techniques to
gather and analyze information.
Our data repository is
continuously updated and revised by a team of research experts, so that it
always reflects the latest trends and information. With a broad research and
analysis capability, Transparency Market Research employs rigorous primary and
secondary research techniques in developing distinctive data sets and research
material for business reports.
Contact
Transparency Market Research,
90 Sate Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.Transparencymarketresearch.com/
